10-Q: Castle Biosciences Reports Q2 Loss Amid Strategic Shifts

Castle Biosciences reported a net loss for the six months ended June 30, 2025, driven by the discontinuation of its IDgenetix test and loss of Medicare coverage for DecisionDx-SCC, despite overall revenue growth.

Summary

• Net revenues increased by 8.9% to $174.2 million for the six months ended June 30, 2025, compared to $159.9 million in the prior year period.
• The company reported a net loss of $21.3 million for the six months ended June 30, 2025, a significant decline from a net income of $6.4 million in the same period of 2024.
• Gross margin percentage decreased to 63.1% for the six months ended June 30, 2025, from 79.4% in the prior year period.
• Dermatologic test revenue decreased by $8.9 million, primarily due to lower average selling price for DecisionDx-SCC following the loss of Medicare LCD coverage in April 2025.
• Non-dermatologic test revenue increased by $23.1 million, largely driven by a 102.2% increase in TissueCypher test report volumes.
• The IDgenetix test offering was discontinued in May 2025, resulting in an accelerated amortization expense of approximately $20.1 million in the first quarter of 2025.
• Operating loss significantly widened to $32.2 million for the six months ended June 30, 2025, from $0.5 million in the same period of 2024.
• Cash and cash equivalents decreased to $82.2 million as of June 30, 2025, from $119.7 million at December 31, 2024.
• Marketable investment securities increased to $193.7 million as of June 30, 2025, from $173.4 million at December 31, 2024.
• The company acquired Capsulomics, Inc. in May 2025 for $18.7 million, with potential contingent consideration of up to $2.5 million.
• An income tax benefit of $5.1 million was recognized for the six months ended June 30, 2025, primarily due to the reduction of a valuation allowance on deferred tax assets following the Capsulomics acquisition.
• The company is constructing a new corporate headquarters in Friendswood, Texas, with an expected total cost of $44.2 million, and $14.0 million spent in the first six months of 2025.
• A new lease agreement for approximately 55,573 square feet of office and laboratory space in Scottsdale, Arizona, was entered into on May 14, 2025, with a 143-month term and $7.2 million in lease incentives.
• The FDA granted Breakthrough Device designation to the DecisionDx-Melanoma test in July 2025.
• The U.S. District Court for the Eastern District of Texas vacated the FDA's LDT final rule on March 31, 2025, which the company believes will not materially impact its existing NYSDOH-approved tests.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant net loss and gross margin decline, primarily driven by the discontinuation of IDgenetix and the loss of Medicare coverage for DecisionDx-SCC. While there's revenue growth from non-dermatologic tests and positive regulatory news (FDA Breakthrough Device designation, LDT rule vacating), the immediate financial performance is concerning. The company's strong cash position and strategic investments for future growth provide some offset, but the path to sustained profitability is challenged.

Positives

• Overall net revenues increased by 8.9% for the six months ended June 30, 2025, reaching $174.2 million.
• Non-dermatologic test revenue saw substantial growth, increasing by $23.1 million, primarily driven by a 102.2% increase in TissueCypher test report volumes.
• The FDA granted Breakthrough Device designation to the DecisionDx-Melanoma test in July 2025, potentially expediting its development and review.
• The U.S. District Court vacated the FDA's LDT final rule, which the company believes will not materially impact its existing NYSDOH-approved tests.
• The company maintains a strong liquidity position with $82.2 million in cash and cash equivalents and $193.7 million in marketable investment securities as of June 30, 2025.
• An income tax benefit of $5.1 million was recognized due to the reduction of a valuation allowance on deferred tax assets, linked to the Capsulomics acquisition.
• The company's 2024 Loan and Security Agreement was amended to extend the $25.0 million credit line draw period until September 30, 2025, providing additional liquidity options.

Negatives

• The company reported a net loss of $21.3 million for the six months ended June 30, 2025, a significant reversal from a net income of $6.4 million in the prior year.
• Gross margin percentage decreased substantially to 63.1% for the six months ended June 30, 2025, from 79.4% in the same period of 2024.
• Dermatologic test revenue decreased by $12.5 million for the three months ended June 30, 2025, and $8.9 million for the six months ended June 30, 2025, primarily due to the loss of Medicare LCD coverage for DecisionDx-SCC effective April 24, 2025.
• The discontinuation of the IDgenetix test in May 2025 resulted in an accelerated amortization expense of approximately $20.1 million, contributing to the net loss.
• Operating loss significantly widened to $32.2 million for the six months ended June 30, 2025, compared to $0.5 million in the prior year.
• Cash and cash equivalents decreased by $37.5 million from December 31, 2024, to June 30, 2025.

Risks

• Inability to achieve sustained profitability in the future due to historical net losses and significant planned investments in commercial organization, clinical studies, and new product development.
• Revenue dependence on DecisionDx-Melanoma and TissueCypher tests, with DecisionDx-SCC revenues expected to decrease significantly in 2025 due to loss of Medicare coverage.
• Adverse effects on business, financial condition, results of operations, or cash flows due to unfavorable U.S. and global economic conditions, including inflation, rising interest rates, geopolitical conflicts (Middle East, Ukraine-Russia), and supply chain disruptions.
• Potential for future changes in regulations or FDA's enforcement discretion for Laboratory Developed Tests (LDTs), which could subject current or future products to extensive FDA requirements and increase costs.
• Inability to effectively manage future growth, including integrating acquisitions (e.g., Capsulomics) and scaling operations, which could strain infrastructure and divert management resources.
• Risks associated with strategic transactions, such as acquisitions, including integration difficulties, increased operating costs, and potential impairment of acquired assets.
• Changes in tax laws or regulations that could adversely affect the business, cash flow, financial condition, or results of operations.
• Disruptions at the FDA and other government agencies due to funding shortages or political processes, potentially delaying product reviews or approvals.
• Legal proceedings, specifically the subpoena from the Department of Health and Human Services, Office of Inspector General, seeking documents related to claims submitted for payment under federal healthcare programs, which could result in significant liability and harm reputation.

Future Outlook

The company anticipates increased expenses due to continued investment in clinical studies, commercialization strategies for current and future products, new product development, and expansion of operational and administrative infrastructure, including the construction of a new corporate headquarters. Profitability and positive cash flows are not guaranteed in future periods, especially given the loss of Medicare coverage for DecisionDx-SCC. The company believes existing cash, marketable securities, and anticipated revenue will fund operations for at least the next 12 months, with longer-term needs potentially met through equity or debt financings.

Management Comments

• We believe our existing cash and cash equivalents, marketable investment securities and anticipated cash generated from our test reports, will be sufficient to meet our cash requirements through at least the 12-month period following the date that these unaudited condensed consolidated financial statements were issued.
• We believe this designation (ADLT status) not only demonstrates our focus on developing and validating innovative tests but also enables our Medicare reimbursement rate to be set, over the long term, by the median private payor rate, which we believe provides a fair exchange of value.
• We believe DecisionDx-UM is the standard of care in the management of newly diagnosed UM in the majority of ocular oncology practices in the United States.
• After careful further assessments, we discontinued our IDgenetix test in May 2025.
• We believe this final ruling (vacating FDA's LDT final rule) will have no material impact on our existing test offerings given all of our tests were marketed before May 6, 2024.
• The Breakthrough Device designation highlights the test's potential to improve melanoma care through individualized prognostic insights.

Industry Context

Castle Biosciences operates in the highly regulated molecular diagnostics industry, focusing on personalized medicine for dermatologic cancers, Barrett's esophagus, and uveal melanoma. The vacating of the FDA's LDT final rule provides some regulatory clarity for existing tests, potentially reducing immediate compliance burdens compared to other LDT providers. However, the loss of Medicare coverage for DecisionDx-SCC highlights the ongoing reimbursement challenges and policy risks inherent in the diagnostic testing sector. The company's strategic acquisitions and investments in new facilities indicate a commitment to expanding its test portfolio and market presence, aligning with broader industry trends towards specialized, high-value diagnostic solutions.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry standard comparisons. However, the company's focus on Advanced Diagnostic Laboratory Test (ADLT) status for its tests (DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, MyPath Melanoma, DecisionDx-UM) indicates an adherence to a high standard of clinical utility and validity, which is crucial for reimbursement in the diagnostics industry.
• The gross margin of 63.1% for the six months ended June 30, 2025, while a decrease from the prior year, should be evaluated against other commercial-stage diagnostics companies, considering the significant fixed costs associated with laboratory operations and the impact of the IDgenetix discontinuation.
• The investment in a new corporate headquarters and laboratory facilities, along with the acquisition of Capsulomics, suggests a long-term growth strategy consistent with companies aiming to scale operations and expand their diagnostic pipeline.

Corporate Governance

Legal Proceedings

• On February 1, 2024, the company received a subpoena from the Department of Health and Human Services, Office of Inspector General, seeking documents and information concerning claims submitted for payment under federal healthcare programs from January 1, 2015, through February 1, 2024. The company is cooperating with the request and is unable to predict the outcome or estimate the amount or range of potential loss.

Stakeholder Impact

• **Shareholders**: Experienced a net loss and decreased gross margin, which could negatively impact stock price. However, strategic investments and a strong cash position may offer long-term value. The CEO's 10b5-1 trading plan indicates planned stock sales.
• **Employees**: Increased headcount from 703 to 798, indicating growth in the workforce. Stock-based compensation expense remains material. Amended participation agreements for key executives provide severance and change-in-control benefits.
• **Customers (Clinicians/Patients)**: Discontinuation of IDgenetix test means this option is no longer available. Loss of Medicare coverage for DecisionDx-SCC may impact access or cost for patients. Growth in TissueCypher test volumes indicates increased access and utility for patients with Barrett's esophagus. FDA Breakthrough Device designation for DecisionDx-Melanoma could lead to improved patient care.
• **Suppliers/Creditors**: The company's strong cash and marketable securities position, along with an available credit line, suggests good financial health to meet obligations. Construction of new facilities and acquisitions indicate continued demand for services and supplies.

Next Steps

• Continue clinical studies to generate evidence supporting current and future product candidates.
• Execute commercialization strategy for current and future commercial products.
• Continue ongoing and planned development of new products in the pipeline.
• Seek to discover and develop additional product candidates.
• Hire additional scientific, research and development, operational, financial, and management information systems personnel.
• Make additional capital expenditures to support business growth and sustain existing operations, including the completion of the new corporate headquarters by early 2026.
• Monitor and respond to the subpoena from the Department of Health and Human Services, Office of Inspector General.
• Manage the integration and scaling of the recently acquired Capsulomics business.

Key Dates

Recommendation

The company's financial performance for the first half of 2025 shows a significant net loss and a substantial decline in gross margin, primarily due to the discontinuation of the IDgenetix test and the loss of Medicare coverage for DecisionDx-SCC. These are material negative impacts. However, the company is actively investing in future growth through the acquisition of Capsulomics, the construction of a new corporate headquarters, and the expansion of its Scottsdale facilities. The strong growth in TissueCypher test volumes and the FDA Breakthrough Device designation for DecisionDx-Melanoma are positive developments. The company also maintains a healthy cash and marketable securities balance, providing liquidity for its strategic initiatives. The legal subpoena from the HHS OIG introduces an element of uncertainty. Given the mixed signals – significant short-term financial headwinds offset by strategic long-term investments and a solid balance sheet – a 'hold' recommendation is appropriate. Investors should monitor the company's ability to offset the lost SCC revenue, achieve profitability from new and growing segments, and manage its increased operating expenses and capital expenditures.

Keywords

Molecular Diagnostics, Dermatologic Cancers, Barrett's Esophagus, Uveal Melanoma, Gene Expression Profile, DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, SEC Filing, 10-Q, Healthcare, Biotechnology, Medical Devices, FDA Breakthrough Device, Medicare Reimbursement, LDT Regulation